

Reviews

Delivery of Large Biopharmaceuticals from Cardiovascular Stents: A Review

Hironobu Takahashi,[†] Didier Letourneur,[‡] and David W. Grainger^{*,†}

Department of Pharmaceutics and Pharmaceutical Chemistry, 30 South 2000 East, Room 301, University of Utah, Salt Lake City, Utah 84112-5280, Inserm, U698, Bio-ingénierie Cardiovasculaire, Université Paris 7, Paris F-75018, France, and Institut Galilée, Université Paris 13, Villetaneuse F-93430, France

Received May 16, 2007; Revised Manuscript Received August 5, 2007

This review focuses on new and emerging large-molecule bioactive agents delivered from stent surfaces in drug-eluting stents (DESs) to inhibit vascular restenosis in the context of interventional cardiology. New therapeutic agents representing proteins, nucleic acids (small interfering RNAs and large DNA plasmids), viral delivery vectors, and even engineered cell therapies require specific delivery designs distinct from traditional smaller-molecule approaches on DESs. While small molecules are currently the clinical standard for coronary stenting, extension of the DESs to other lesion types, peripheral vasculature, and nonvasculature therapies will seek to deliver an increasingly sophisticated armada of drug types. This review describes many of the larger-molecule and biopharmaceutical approaches reported recently for stent-based delivery with the challenges associated with formulating and delivering these drug classes compared to the current small-molecule drugs. It also includes perspectives on possible future applications that may improve safety and efficacy and facilitate diversification of the DESs to other clinical applications.

1. Introduction

Stenting—the surgical placement of an intravascular hollow cylindrical device into vascular lesion sites following percutaneous transluminal coronary angioplasty (PTCA)—is a common procedure to inhibit vessel restenosis, particularly in the coronary vasculature. However, in-stent restenosis is observed at the stented site in 15–20% of PTCA patients following bare metal stent implantation.^{1–4} Clinical trials using systemic drug administration (i.e., parenterally administered anti-restenotic agents) have failed. This is attributed to insufficient drug doses actually reaching the vascular target site and adverse systemic side effects.^{1,5–7} This emphasizes the importance of local delivery directly from the stent surface to influence local cell populations in the vascular wall. To reduce doses required and the incidence of systemic complications and ensure appropriate drug dosing directly at the target site, drugs can be directly and continuously

delivered to the tissue of interest. Catheter-based delivery devices have been developed to locally deliver drugs to vascular sites as well to perform PTCA.^{1,7} However, beyond simple drug delivery, controlled release of therapeutic agents to specific targets, primarily anti-restenotic agents at stented sites, is often required. Drug-eluting stents (DESs) provide anti-restenotic drug therapy with low-dose local drug delivery from the coated stent surface to the vessel tissue bed has rapidly become a clinically routine therapeutic approach to inhibit in-stent restenosis to less than 5% in millions of cases annually.⁸ The DES comprises a dose of drug typically embedded within a carrier coating (generally polymer but also inorganic phases) applied to the wire mesh comprising the stent.^{3,9}

Implantation of bare metal stents, while common, in principle presents a highly reactive metal surface known to activate coagulation cascades, produce thrombosis and inflammatory reactions, and release toxic metal ions (i.e., chromium, nickel, or molybdenum).¹⁰ Surface modification has been known for over four decades to improve metal–blood compatibility. Hence, stent coating is popular both to produce a local drug release matrix as well as limit intrinsic thrombogenicity and foreign

* Author to whom correspondence should be addressed. Phone: (801) 581-4532 (Department Office). Fax: (801) 581-3674. E-mail: david.grainger@utah.edu.

[†] University of Utah.

[‡] Université Paris 7 and Université Paris 13.

body responses. Carbon coating is used without drug loading to produce a passivating surface with claims to improved biocompatibility in vitro and in preclinical testing.^{11–14} However, as these carbon coatings have been extended to human stent trials, performance in vivo has been nondistinguishing, reducing the enthusiasm for carbon-coated stents in human implants.^{15–17} Synthetic polymers, hydrogels, and polysaccharide coatings provide a reasonable coating matrix with reduced procoagulant activity compared to bare metal stents. Bioactive agents (drug dose of approximately micrograms/stent) loaded into these coatings are intended for local release to affect specific cell types in the vascular wall following stent intravascular deployment. To produce desired pharmacological effects while avoiding side effects, the DESs must be designed to limit drug release prior to deployment and release the proper dosing at the desired kinetics after deployment. Additional important DES design criteria are (1) minimal thrombogenic DES procoagulant or complement activation in the blood stream, (2) acceptable stent and coating stability in the vascular wall upon placement, (3) solubility compatibility between polymer, solvent, and drug during the coating formulation process, and (4) coating stability and integrity during stent deployment where shape-memory or luminal expansion effects produce mechanical stress and strain.

Many previous reviews have extensively documented the current U. S. Food and Drug Administration (FDA)-approved clinical methodologies and pharmacologies and expected related innovations, all emphasizing smaller-molecule drug release.^{1,6,18–20} Nevertheless, newer emerging DES designs are using increasingly sophisticated bioactive agents, including new macromolecular drugs (e.g., proteins, nucleic acids, or viral vectors) with unique pharmacologies but also specific delivery requirements. Device-based delivery approaches that have shown clinical efficacy to date with small drugs do not necessarily translate to efficacy with biopharmaceuticals. It is likely therefore that many aspects of controlled release DES formulations used in coronary stenting will require redesign to both accommodate dosing and delivery issues for large-molecule drugs and distinct pathology and pharmacology in many other cardiovascular stenting sites.

2. Overview of Small-Molecule Therapeutics in DES Designs

Several clinical trials have already shown that rapamycin (e.g., CYPHER, RAVEL, SIRUS) and paclitaxel (e.g., ASPECT, ELUTES, or TAXUS) eluted from polymer-coated stents exhibit superior performance in preventing vessel restenosis compared to bare metal stents.^{9,18,19,21–26} Within cells, sirolimus inactivates the mammalian target of rapamycin (mTOR) by forming a complex with FK506-binding protein 12 (FKBP12). As a result, the down-regulation of kinase p27 is prohibited, inhibiting passage of the cell cycle from the G1 to the S phase and preventing cell proliferation.⁹ In contrast, paclitaxel binds to β -tubulin, resulting in inhibition of microtubule depolymerization in a dose-dependent fashion. At high concentrations, this inhibits smooth muscle cell (SMC) proliferation and migration by disturbing the cell's M phase.²⁵ As shown in this review, there may be many other strategies now evolving to produce the same targeting of proliferating, mobilized cell types in the vascular bed more specifically, with improved efficacy and safety for DES deployment.

Since the approval of the sirolimus-eluting stent by the FDA, various sirolimus analogues including zotarolimus (ABT-578), biolimus-A9, and everolimus have also been shown to be effective against restenosis (e.g., ENDEAVOR, FUTURE, and other trials) in DES formats.^{19,20,27–29} Sirolimus-eluting DESs

Table 1. Small-Molecular-Weight Anti-restenotic DES-Based Drugs

drug	MW	references
sirolimus	914.1	9, 21
zotarolimus	966.2	28, 29
everolimus	958.2	27
tacrolimus	822.0	57, 58
paclitaxel	853.9	22–25
actinomycin D	1255.4	45
cytochalasin D	507.6	56
dexamethasone	392.4	44, 59
17- β -estradiol	272.3	60, 61
mycophenolic acid	320.3	20
angiopeptin	1096.3	54
cyclic RGD-containing peptide	948.0	55

may also elicit adverse effects as rapamycin pharmacology is not specific to cell type but more generally toward all proliferating phenotypes. In particular, recent studies suggested that DES implantation adversely affects local endothelium regeneration.^{30–33} While the coronary arterial stent represents substantial clinical impact, other more difficult stenting sites are current targets for new DES techniques, seeking to demonstrate efficacy in challenging diabetic patients^{34–36} and more complex disease sites, for example, small vessel^{22,37} and bifurcated lesions^{38–40} and peripheral vasculature including venous sites.^{41–43} Thus, new stent designs will likely be combined with new therapeutic drug mixtures. For example, stent coatings releasing dexamethasone (STRIDE) and actinomycin D (ACTION) are shown to inhibit SMC proliferation.^{44,45} Nitric oxide (NO) with its potent modulation of several significant vascular events including SMC proliferation^{46–48} and select bioactive peptides with specific binding activities (cyclic Arg-Gly-Asp (RGD)-containing peptides, angiotensin, and angiopeptin^{49–51}) might also be candidates for DES-released anti-restenotic agents. Recently, anti-restenotic effects of NO donor-loaded stents have been investigated.^{52,53} Angiopeptin blockade of growth-factor-induced SMC proliferation⁵¹ and of platelet receptors that inhibit platelet aggregation by RGD-containing peptides,⁴⁹ relevant peptide-eluting stents, might demonstrate efficacy in reducing neointimal hyperplasia.^{54,55} Recently, the delivery of microfilament inhibitor, cytochalasin D, produced significant inhibition of platelet aggregation and SMC proliferation in pig coronary arteries compared with that of paclitaxel.⁵⁶ In summary, many different bioactive agents have been or are being screened to address in-stent restenosis, targeting many different cellular mechanisms in the vascular bed.

Drug therapeutic efficacy in stent-based delivery depends upon many factors, including:

- local physiology (i.e., venous vs arterial sites or vessel lesion pathology)
- drug pharmacology (specificity or potency) and toxicity
- stent-based drug formulation (dose, release rate, bioavailability, or duration)

Effective drug dosing and dose release from stent coatings depends on many factors including potency, local pharmacology and toxicity, clearance, formulating constraints on-stent, and drug physicochemical properties (molecular weight, stability, chemistry, and solubility). To date, most drugs loaded onto and released from stents are relatively low-molecular-weight compounds (e.g., 400–900 Da). Current small-molecule therapeutics in this context have been well-documented and often reviewed^{1,6,18–20} and are summarized in Table 1. Small-molecule drugs provide several strategic advantages in dosing and formulation: Smaller

drugs tend to be more robust than large biological drugs (i.e., proteins or nucleic acids), and amounts of drug (i.e., moles) are larger per unit mass formulated. Nevertheless, at present, a diverse array of candidate drugs is required to address various targets against restenosis (i.e., inhibition of neointimal hyperplasia), thrombosis, blockade of inflammatory responses, and promotion of re-endothelialization.^{2,4,5} Use of new, relatively high-molecular-weight molecules expands therapeutic possibilities of drugs and their targets for stent-based delivery systems. Currently, innovative new biopolymer-based therapeutics (RNAi, DNA transgenes, proteins, and polysaccharide drugs) are being investigated for stent-based delivery against numerous targets. While primarily focused on anti-restenotic effects, these drug candidates could provide appropriate treatments and diverse bioactive actions beyond this treatment regimen in the future, depending the respective lesions and stent formulations.

3. Nucleotide-Based Drugs for Stent-Based Delivery

3.1. DNA-Based Drugs. Gene therapy—the deliberate exogenous delivery of a therapeutic transgene⁶²—is currently being evaluated in hundreds of clinical trials for various conditions. It also offers the potential for new treatments for specific cardiovascular diseases, both systemically and from the surfaces of cardiovascular devices.^{63–67} DNA plasmids encoding an anti-restenotic transgene can be directly perfused or injected at an injury site using catheters. While naked DNA plasmids are commonly used, transgene vectors—various viral or nonviral polymers or lipid carriers of the DNA therapeutic gene—can be exploited to facilitate necessary gene penetration into cells and into the nucleus. However, in all cases, control of the possible systemic bio-distribution of the therapeutic gene is required. Transgene uptake into vascular tissue sites takes time, so to prevent systemic distribution of the catheter-based gene therapy dose from vascular flow, direct perfusion methods often temporarily halt blood flow in the vasculature surrounding the lesion, infuse the dose via catheter, incubate the transgene dose under no-flow conditions, rinse with saline, then restore normal vascular flow. To prevent hypoxia or necrosis, intravascular perfusion times cannot exceed minutes, limiting dose penetration to the desired site and increasing prospects for systemized exposure. In contrast, stent-based gene delivery puts a smaller transgene dose on the stent surface, places the delivery surface directly into contact with the vascular bed to better deliver a reliable and local dose without systemic issues or kinetic delivery limitations. Tissue penetration from locally delivered doses is conceivably a much more attractive method to control adverse systemic side effects while attempting to inhibit restenosis.

Biodegradable polymer coatings with a strong medical device track record, FDA approval in a number of therapeutic contexts with accepted biocompatibility and drug reservoir capacities, degradable FDA-approved polymer coatings comprising poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), poly-(caprolactones) (PCL), and polyglycolic acid (PGA) have been often used for stent coatings as well as completely degradable stents.^{68,69} Bioresorbable polymers show high tensile strength, controlled degradation rates, and reliable fatigue properties.⁷⁰ Importantly, these biodegradable polymers also have been used as nonviral gene vectors for over a decade.^{71,72} For example, plasmid DNA is loaded into polylactic–polyglycolic acid (PLGA) on a bare metal stent by stent immersion into a PLGA emulsified organic–aqueous solution containing plasmid DNA (e.g., model green fluorescent protein (GFP) plasmids, 0.9–1.1 mg of DNA loaded into 8–9 mg of PLGA emulsion on a




Figure 1. Balloon-expanded arterial stents without (left) and with DNA–PLGA coating (right) (with Nile Red dye for visualization). Reprinted with permission from ref 73. Copyright 2000 Macmillan Publishers Ltd.




Figure 2. Cell transfection with GFP plasmid DNA into A10 cells using a DNA–PLGA-coated stent wire. Line indicated by arrows shows the original location of the coated steel rod's edge at the perimeter of the GFP-positive cells (200 $\times$). Reprinted with permission from ref 73. Copyright 2000 Macmillan Publishers Ltd.

Crown stent, Figure 1), producing a coating.⁷³ As shown in Figure 2, plasmid DNA releases from the stent coating and transfects cells locally within the vascular wall. Additionally, non-degradable polymer coatings might better be used to deliver plasmid DNA release from stents⁷⁴ while also limiting associated thrombosis issues after stent implantation using polymer coatings comprising biomedical polyurethanes, heparin sulfates, and other glycosaminoglycans, hyaluronic acids, and other hydrophilic polymers (e.g., hydrogels). To date, polymer coatings have been used to demonstrate the possibility for local gene delivery from gene-eluting stents. However, stent-based gene delivery would likely require a transfection system (e.g., vector) for efficacious gene expression. Vectors are either viral (e.g., gene-loaded adenovirus or adeno-associated virus (AAV)) or nonviral (cationic synthetic polymeric or colloidal electrostatically complexed transgenes).^{62,72,75,76} Muhs et al. performed gene delivery by catheter injection of plasmid lipoplexes with cationic lipids into pig coronary arteries in vivo,⁷⁷ demonstrating that these complexes of plasmid DNA encoding nitric oxide synthase (NOS) and lipids could produce gene expression sufficient to inhibit SMC proliferation and migration, attributed to the anti-restenotic activity of expressed NOS as an NO producer.^{78,79} However, while claims to efficacy are often made for such transgene systems in vitro (e.g., in serum-free media), further improvements in transfection efficiency and duration of expression are needed to achieve significant inhibition of restenosis in vivo from nonviral vectors. Thus, while polymer-based (e.g., nonviral) gene delivery agents might effectively produce local arterial gene transfer,⁸⁰ their use in gene delivery from stents has been quite limited to few studies.^{73,81}

Because of their higher intrinsic transfection efficiency, viral vectors have realized significant reduction in neointimal formation using therapeutic genes.^{82,83} Adenoviral vectors in particular have been studied for therapeutic effects on hyperplasia and restenosis.^{63,64,79,84,85} For example, adenovirus encoding PTEN, an intracellular protein regulator inhibiting neointimal hyperplasia, was injected into ligated rat carotid artery under no-flow conditions, reducing neointimal hyperplasia.⁸⁵ Ye et al. reported stent-based delivery of adenovirus encoding β -galactosidase using bioresorbable microporous stents comprising a polylactide/polycaprolactone blend for the stent coating.⁸⁶

At present, stent-based drug loading is realized primarily by direct application of polymer solutions containing the drug of choice to stent surfaces (dip coating or spray coating). Many polymers of interest are not readily water-soluble, producing problems for the stability of many attractive biologically derived drugs in organic media. As an alternative, collagen can be used as a base coating capable of drug physical incorporation, direct collagen bioconjugation, and drug surface coupling. Recently, stent spray coating using collagen solutions mixed with drug was investigated.⁸⁷ Collagen coating also provides significant biocompatibility, biodegradability, and tensile strength to stenting.^{88–90} Combined use of adenoviral vectors and collagen using antiviral antibodies covalently conjugated to precoated collagen and subsequent gene-loaded viral binding to the antibody has been reported.^{91–93} Stainless steel stents were coated with bovine type I collagen by immersion into collagen solutions. Anti-knob (Fab)'2 antiviral antibodies were conjugated with collagen activated with standard thiol coupling reagents (SPDP), and then viral particles loaded with transgenes were bound by simple association. Adenovirus encoding GFP loaded on-stent produces GFP local expression in cultured SMCs around this collagen-coated stent. A surface density of 2.5×10^{10} viral particles per milligram of collagen was achieved by this technique, and adenovirus was successfully delivered into coronary arteries upon deployment in vivo as shown by GFP expression in a stented coronary artery.⁹¹ Denatured collagen (gelatin) was used to deliver naked plasmid DNA encoding GFP without adenoviral vectors.⁹⁴ Enhanced gene expression was proposed to be enhanced by specific interaction of denatured collagen with the SMC $\alpha_v\beta_3$ integrin.^{95,96} In this system, 500 μ g of plasmid DNA produced $10.4\% \pm 1.23\%$ neointimal cells expressing GFP in a pig coronary artery.

Recently, stent-based polymer coatings have been correlated with late thrombosis, inflammation, and restenosis,^{97–102} prompting some approaches to deliver bio-active agents from stent surfaces without coatings. Sirolimus-eluting stents have been reported without polymer coating.^{103,104} Rapamycin is loaded onto stainless steel microporous stents by spray coating with rapamycin solutions. This drug-loaded stent produced significant inhibition of neointimal formation in a coronary artery stent model. Fishbein et al. reported adenovirus loaded directly onto metal stents without polymer coating.¹⁰⁵ Because bisalkylphosphonates exhibit high-affinity binding activity to certain metallic oxide surfaces through phosphonate–metal coordination,^{106,107} adenovirus vectors have been loaded on metal stents using polyallylamine grafted with bisphosphonate and modified with anti-adenovirus antibodies as shown in Figure 3. Local delivery of adenovirus encoding inducible NOS from the stent showed significant therapeutic effects following rat carotid stent implantation with inhibition of restenosis compared with bare metal stents.

Phosphorylcholine (PC)-based copolymer coatings have been reported to enhance stent blood- and bio-compatibility.^{108–110}




Figure 3. Schematic illustration of adenoviral vector conjugation to a bisphosphonate-modified metal surface for direct gene delivery upon deployment. Reprinted with permission from ref 105. Copyright 2006 National Academy of Sciences, U.S.A.




Figure 4. Effects of local phVEGF delivery on endothelialization (A) and mural thrombus (B) at stented sites in iliac arteries at 7 days after catheter injection. Reprinted with permission from ref 116. Copyright 1997 American College of Cardiology.

Large numbers of PC analogue polymer coatings have been developed for DESs as well as biodegradable polymer coatings,^{28,29,44,54,60,61,111,112} including that currently commercialized by Abbott Labs' DES (ENDEAVOR trial).²⁰ Walter et al. reported local delivery of plasmid DNA encoding vascular endothelial growth factor 2 (VEGF-2) from PC-coated stents.¹¹³ Because of the acceleration of re-endothelialization,^{2,4,5} local delivery of VEGF is useful to reduce neointimal formation^{114,115} as shown using catheters to deliver the VEGF gene at balloon-injured sites (Figure 4).^{116,117} In stent-based delivery, PC coating enabled loading of $\sim 200 \mu$ g of VEGF-2 plasmid, achieving a reduction of SMC proliferation in rabbit iliac arteries. Tissue inhibitor of metalloproteinase (TIMP) is also a potentially therapeutic gene against restenosis because it limits matrix metalloproteinase (MMP) activity and has direct effects on cell growth. In this regard, gene expression of TIMP in SMCs was reported to inhibit neointimal formation.^{118,119} In particular, the study demonstrated that TIMP-3 was superior to TIMP-2 for inhibition of neointimal formation in pig vein grafts.^{120,121} A follow-on study demonstrated that local delivery of adenovirus encoding TIMP-3 from PC-coated stents successfully reduced neointimal formation in a pig coronary model.¹²²

While adenoviral vectors have produced high gene expression in many studies using gene-eluting stents, more recently AAV has become a next-generation focus because of its high safety profile and preference in clinical trials to disease.⁸³ Because AAV serotype 2 (AAV2) has been particularly investigated,




Figure 5. Difference in gene expression profiles between adenoviral and adeno-associated viral (AAV) delivery from their respective gene-eluting stents. Relative expression of the lacZ reporter gene released from adenovirus (dashed line, 10^9 PFU) or AAV-eluting stents (solid line, 10^9 drp) into the neointima of rabbit external iliac arteries at 14, 21, and 28 days following stent deployment. Adapted from ref 123.

Sharif et al. loaded AAV2 encoding model β -galactosidase onto PC-coated stents.¹²³ Though no difference in transfection activity between AAV2-eluting and adenovirus-eluting stents was observed, release kinetics for up to 28 days distinguished the former from the latter approach (Figure 5). Importantly, different AAV serotypes are expected to show different transfection activities depending on targeted cell and tissue types.^{76,124} Hence, further study of AAV-eluting stents should better clarify specific effects of AAV on the potential inhibition of restenosis and other stent-associated issues.

Stent-based delivery allows lower doses of therapeutic genes compared with systematic gene delivery or even local catheter-based intravascular infusion. Control of the transgene dose and distribution is essential to improve and optimize the effect of gene delivery on restenosis. Local dose tissue processing, pharmacokinetics, and expression duration of most delivered genes are virtually unknown. Systemic fate and viral vector distribution analysis is limited by method detection limits. As described above, stent coatings of biodegradable synthetic polymers, collagen, and PC are primary techniques for gene-eluting stents to date. The polyelectrolyte layer-by-layer (LBL) technique is also becoming more useful for controlled local release of DNA to tissues and cells.^{125,126} Polymer electrostatically based multilayer coating formation enables control over DNA loading and possibly transfection efficiency. Additionally, it is expected to protect plasmid DNA loaded on-stent from ubiquitous nuclease digestion.^{127,128} A recent study demonstrated gene delivery from a stent coated with polyelectrolyte multilayers.⁸¹ Plasmid DNA encoding GFP was delivered from a multilayered film of the degradable cationic polymer, poly(β -amino ester), and DNA to cultured COS-7 cells in vitro, producing GFP expression. In other studies, Nakayama et al. developed a gelatin-based photocuring coating system triggered by visible laser.¹²⁹ Brief laser irradiation on a stent immersed in gelatin solution produced a hydrogel coating on the stent by photopolymerization of styrene-grafted gelatin.¹³⁰ Adenoviral vector encoding model β -galactosidase was delivered from the photocurable gelatin-coated stent to rabbit carotid arteries. Drug release rate from the photocurable gelatin was controlled by the cross-linking density and gel density.¹³¹ Thus, these stent coating strategies could be useful to achieve significant loading and controlled release of anti-restenotic genes from stents.

3.2. Antisense Oligonucleotides. Antisense oligonucleotide (ODN) delivery can effectively modulate gene expression within cells, with therapeutic potential.^{132,133} Antisense ODN interference in critical steps in the SMC growth cycle has been investigated using cdc2 kinase, proliferating cell nuclear anti-




Figure 6. Schematic representations of three common oligonucleotide analogue chemistries used in therapeutics.

gen,¹³⁴ the ERK family of mitogen activated protein kinases (AMK1),¹³⁵ early growth response factor 1 (Egr-1),¹³⁶ and other targets. As noted for other antisense therapies, chemical modifications of antisense ODN influence antisense strategies for the treatment of restenosis.¹³³ Gunn et al. reported that because of their nuclease stability and relative ease of synthesis, phosphorothioate-ODN (S-ODN) (shown in Figure 6) may effectively reduce neointimal formation after PTCA, compared to unmodified ODNs.¹³⁷ For example, S-ODN against Midkine successfully inhibited neointimal formation following stent implantation.¹³⁸ To obtain high transfection activity, the antisense ODN was injected with LipofectAmine reagent (Invitrogen) directly to the injured area. However, it was concluded that Midkine antisense ODN effects were not sufficient to significantly suppress neointimal formation. That is, selection of the anti-restenosis therapeutic target is as important as ODN delivery efficiency to the target site. A very recent study reported that stent-based delivery of S-ODN targeted to platelet-derived growth factor (PDGF) A-chain significantly decreased in-stent restenosis in porcine coronary artery.¹³⁹ Immersion of hydrogel-coated stents into a S-ODN solution containing polyethylenimine was used to produce antisense ODN-coated stents. Importantly, differences in endothelialization between antisense ODN-targeted PDGF A-chain and sirolimus-eluting stents were shown in vivo. In contrast to sirolimus that prevents not only SMC proliferation but also vascular re-endothelialization, resulting in late thrombosis, these data suggested that vascular delivery of antisense ODN-targeted PDGF A-chain did not interfere with endothelialization.

C-myc, a short-lived sequence-specific DNA-binding nuclear phosphoprotein and regulatory transcription factor, is the most effective target to date in antisense therapy for restenosis. Shi et al. reported that local delivery of antisense S-ODN against c-myc showed potential to reduce neointimal formation in a coronary artery balloon injury model.¹⁴⁰ To achieve stent-based delivery of c-myc targeting S-ODN, the S-ODN (550 μ g) was loaded into gelatin-coated platinum-iridium stents and released into a rabbit carotid artery model.¹⁴¹ While local delivery of antisense S-ODNs against c-myc effectively inhibited SMC proliferation, Kutryk et al. reported that injection of 10 mg of S-ODN directly into the stented site did not significantly reduce neointimal formation;¹⁴² one set of conclusions is that either S-ODN is not the most effective chemically modified ODN for inhibition of restenosis or that soluble S-ODN injection is not as effective in producing a local effect versus coating-based delivery of the ODN-based therapeutic.

Morpholino-backbone antisense ODN against c-myc is also a potent alternative candidate therapeutic drug against restenosis.^{143–145} As neutrally charged nucleic acid analogue oligomers, morpholino nucleotides (MOs) represent an unusual DNA chemistry with a nucleobase tethered to a six-membered morpholine ring and an uncharged phosphorodiamidate linkage (compare struc-




Figure 7. Molecular structure of synthetic cationic phosphorylcholine (PC)-based copolymers used for stent-based release coatings. Reprinted from ref 147. Copyright 2006 American Chemical Society.




Figure 8. Controlled release of antisense S-ODN from different PC copolymer films (choline methacrylate monomer content: 0%, $\diamond$; 5%, $\blacksquare$; 10%, $\blacktriangle$; 20%, $\times$) into PBS buffer at pH 7.4. Reprinted from ref 147. Copyright 2006 American Chemical Society.

tures in Figure 6).^{133,146} As MOs have high nuclease resistance and antisense activity against mRNA, inhibiting translation, Summerton reported that MO antisense activity often achieved equal or better efficacy compared with S-ODNs.¹⁴⁶ Kipshidze et al. used antisense MOs against c-myc for inhibition of neointimal formation in the porcine coronary model, confirming that catheter-based local delivery of antisense MOs significantly reduced neointimal formation.^{143,144} Moreover, they performed stent-based delivery of antisense MOs by immersing a polymer-coated stent into 30 mg/mL MO solution for 5 min, yielding $81.5 \pm 14.4 \mu\text{g}$ of antisense MOs on a PC-coated stent.¹⁴⁵ MO charge neutrality protected these antisense ODNs from interactions with charged biological species (proteins or lipids), perhaps providing more efficient interactions with target mRNA to enhance cellular uptake of c-myc antisense ODNs. Recent studies, in contrast, used conventional antisense S-ODNs with a cationic PC copolymer to control ODN loading and release^{147,148} using a previously reported PC copolymer.^{149,150} Cationic charge density was controlled by copolymerizing cationic co-monomers with choline methacrylate as shown in Figure 7. The loading amount and the release kinetics of S-ODNs were controllable by the combined use of S-ODN and cationic PC coating as shown in Figure 8. In contrast to the MO utility, considering that drug loading is a key factor for drug-eluting stent efficacy, the S-ODN anionic charge density could be useful to optimize stent-based delivery.

3.3 Decoy ODNs. While several antisense strategies have been investigated to inhibit restenosis, therapy using decoy ODNs also provides efficient cell cycle modulation for treating certain cardiovascular diseases.¹⁵¹ Nuclear factor kappa B (NF- κ B) is a most popular target against restenosis in the ODN decoy strategy.^{152–154} NF- κ B plays a critical role in coordinated gene transactivation of cytokines and cell adhesion molecules.




Figure 9. Effects of NF- κ B decoy-eluting stents on vascular wall mRNA levels of various pro-inflammatory factors and tissue factor (TF) at 10 days after stenting (MCP, monocyte chemoattractant protein; IL, interleukin; TNF, tumor necrosis factor; PDGF, platelet-derived growth factor; VCAM, vascular cell adhesion molecule). Adapted from ref 157.

Kitamoto et al. reported that transfection of NF- κ B decoy ODNs into coronary arteries after coronary angioplasty inhibited SMC proliferation.¹⁵² Clinical application of the NF- κ B decoy in reducing restenosis after PTCA was until now investigated in only two patients.¹⁵⁴ In experimental studies, Kalinowski et al. reported that NF- κ B decoy delivery using a balloon catheter did not significantly reduce neointimal formation in rabbit iliac arteries,¹⁵⁵ and Radke et al. loaded decoy NF- κ B ODNs onto stents coated with a cationic PC copolymer for better control of loading and release demonstrated by successful ex vivo ODN deposition in the vessel wall.¹⁵⁶ As for antisense ODNs against c-myc,^{147,148} ODN loading amount was controlled by cationic charge density in the polymer coating and the ODN concentration. As a result, a PC copolymer coating containing 20% cationic co-monomer was maximally loaded with $41 \pm 6 \mu\text{g}$ of decoy ODNs (3×10^{12} ODN molecules) on-stent. This decoy ODN-eluting stent provided significant antisense transfer into vessel walls in ex vivo experiments. However, this did not result in significant reduction of SMC proliferation after stent implantation in vivo. These data suggest that rapid intravascular release of ODNs prior to or concomitant with stent implantation and penetration through other potential physiological barriers to antisense transfer (e.g., lesions, thrombus, or cholesterol plaques) must be improved to obtain a significant effect on restenosis. On the other hand, Ohtani et al. observed that stent-based local delivery of NF- κ B decoy reduced in-stent neointimal formation in iliac arteries of hypercholesterolemic rabbits.¹⁵⁷ This study reported that rapid release (<7 days) of NF- κ B decoy from polyurethane-coated stents inhibited in-stent neointimal formation. Their results, shown in Figure 9, indicated that stent-based delivery of NF- κ B decoy reduced NF- κ B-dependent gene expression (e.g., monocyte chemoattractant protein 1 (MCP-1), interleukin 1, or interleukin 6) but not for NF- κ B-independent genes (e.g., PDGF).

Currently, many potent new targets against restenosis have been discovered and advocated. This means that various types of therapeutic approaches and molecules now available must be matched with specific drug-eluting techniques required to produce optimal efficacy in vivo. DES therapeutic value will strongly depend on the balance of loaded drug pharmacology, release kinetics, loading method (coating polymer), site of deployment, basic stent platform, and patient variables. Stent-based delivery of plasmid DNA encoding NOS, antisense ODN against c-myc, and NF- κ B decoys have been investigated in preclinical trials but with mixed, equivocal results. Data to date

do not clearly suggest a rational route to improve these results, but progress with these biological drugs will allow extension of the techniques to other therapeutic agents.

4. Protein Therapeutics

4.1. Therapeutic Antibodies and Affinity Protein Ligands.

Over 20% of new drug applications are antibody-based therapeutics. It is likely that this highly successful drug class will find application in DESs. Accumulation of activated inflammatory cells and release of chemotactic inflammatory mitogenic cytokines upon acute injury from stent implantation are important factors inducing SMC mobilization, proliferation, and migration. Thus, blockade of local inflammatory responses is a common technique to attempt to inhibit neointimal formation.^{4,7} For example, the inflammatory cytokine, tumor necrosis factor α (TNF- α), is expressed by SMCs in balloon-injured sites, activating SMC migration.¹⁵⁸ Blockade of TNF- α with a soluble TNF- α receptor efficiently inhibited coronary neointimal formation.¹⁵⁹ A monoclonal anti-TNF- α antibody exhibited high anti-proliferative activity, resulting in significant reduction of SMC proliferation by neutralization of TNF- α .¹⁶⁰ Antibody loading was achieved by immersion of a cellulose polymer-coated stent in anti-TNF- α antibody solution.¹⁶¹ About 0.25 μ g of antibody per milligram of stent achieved marked reduction of SMC proliferation in human saphenous vein organ cultures. Specific neutralization of SMC TNF- α by the antibody might avoid unwanted side effects in other cells.¹⁶⁰ As expensive, large (~160kDa globular proteins) glycosylated therapeutics, antibodies require new delivery strategies for specialized local delivery;¹⁶² stent-based delivery of therapeutic antibodies has a large unexplored potential against numerous targets.

Anti-platelet therapy potentially reduces intimal formation induced by platelet aggregation. Platelet glycoprotein receptor GPIIb/IIIa has an important role in platelet activation and remains a clinical target to inhibit thrombosis.¹⁶³ Monoclonal antibodies against the human GPIIb/IIIa receptor provide significant inhibition of platelet aggregation when systemically infused in human therapies (abciximab, c7E3, ReoPro, Centocor, Inc.). An anti-rabbit GPIIb/IIIa receptor antibody, AZ1, has been used to inhibit platelet function at vascular injury sites.¹⁶⁴ Aggarwal et al. reported local delivery of AZ1 from cellulose polymer-coated stents loaded by direct immersion of cellulose-coated stents into AZ1 coating in solution.¹⁶⁵ After 24 h of incubation in 1 mg/mL AZ1 coating solution, an antibody density of 104.3 ± 1.3 ng/10 mm stent wire segment with more than 14 days of continuous release was achieved. However, this stent-based delivery system did not significantly inhibit neointimal formation in vivo.

Blockade of the $\alpha_v\beta_3$ integrin (vitronectin receptor) on SMCs efficiently inhibits SMC proliferation and migration.¹⁶³ Cyclic RGD peptide binds to $\alpha_v\beta_3$ integrin, reducing neointimal formation where delivered.⁴⁹ Cyclic RGD-eluting stent implantation effectively inhibits neointimal hyperplasia.⁵⁵ The human monoclonal antibody against human platelet GPIIb/IIIa, abciximab (c7E3, ReoPro), also has the ability to bind cell vitronectin receptors including $\alpha_v\beta_3$ integrin because of its relatively nonspecific binding property.^{163,166} Thus, abciximab with intrinsic high anti-platelet activity administered by an intravenous dose has been used in stent implantation.¹⁶⁷ However, the delivery strategy must be considered to optimize significant benefits.¹⁶⁸ Considering that the rabbit AZ1 anti-platelet antibody has no measurable affinity against the cell vitronectin receptor¹⁶⁵ and produced no anti-restenotic activity in vivo, selective receptor targeting abilities to produce effective therapy could

be very subtle for the success of anti-platelet agents: Binding activity to SMC vitronectin receptor may be clinically advantageous to inhibit both platelet aggregation and neointimal hyperplasia in situ. Abciximab-loaded polymer-coated GR11 stents (Cook, Inc.) produced slow antibody release from the stent (approximate 50% stent release over 12 days) by simple immersive loading.¹⁶⁹ Abciximab also has been covalently attached to stent surfaces using plasma polymerization.^{170,171} The loading produced 90 μ g/stent of slow antibody release, likely by hydrolysis. In vivo antibody bioactivity remains unknown. While antibody doses and optimal release kinetics are virtually unknown, stent-based delivery allows much lower antibody dosing locally (μ g) compared with systemic doses ($\gg$ mg), but due to the fragility of these globular protein therapeutics, specific assays of antibody bioactivity postrelease must be carefully assessed.¹⁶²

4.2. Release of Vascular Endothelial Growth Factor. Rapid vessel re-endothelialization is an attractive strategy to inhibit SMC proliferation.^{4,7} Both host endogenous circulating endothelial cells (ECs) and endothelial progenitor cells (EPCs) are actively recruited to the stented site for re-endothelialization.^{172–174} Chemotactic mitogenic cytokines such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) can act in this capacity as potent mitogenic agents of ECs and EPCs.^{89,175} Local delivery of VEGF^{114,115} and plasmid DNA encoding VEGF^{113,116,117} was shown to prevent restenosis by acceleration of neovascularization and re-endothelialization at the injured site. Stent-based VEGF delivery was also performed by immersion of polymer-coated stents into VEGF aqueous protein solutions loading 18.5 ± 4.1 μ g of VEGF on a 3 mm $\times$ 20 mm stent after 2 h of immersion.¹⁷⁶ Slow VEGF release from the stent increased growth of cultured human umbilical vein endothelial cells (HUVECs) in vitro.

In most stent-based delivery systems, drug loading (dose) is a critical factor due to the limited on-stent drug loading capacity (i.e., wire coating). Dosing relationships and kinetics of release necessary to produce long-term efficacy are often thought to be dose-limited. In addition, most protein drugs are low stability, large-molecular-weight, large-dosage-amount agents with difficult formulation requirements.^{177,178} This has produced a shift from direct delivery of the therapeutic protein to delivery of the transgene coding that protein, with an expected longer duration of the protein dose at the locally transfected site. However, compared with delivery of plasmid DNA encoding VEGF, VEGF protein delivery has the advantage of asserting the effect of the known dose of delivered VEGF. In vitro efficacy of VEGF-eluting stents in promoting endothelial cell growth does not correlate with insignificant effects of the VEGF-eluting stent system in vivo using a rabbit iliac artery model.¹⁷⁶ Recently, use of a thermo-responsive polymer as a VEGF release vehicle was reported to improve dosing and efficacy.¹⁷⁹ Additionally, use of truncated, lower-molecular-weight recombinant protein fragments with the desired potency and improved stability (e.g., VEGF₁₂₁ or VEGF₁₆₅)^{115,180} could improve stent-based delivery approaches.

4.3. Protein C Delivery from Stent. Protein C and protein S manifest important roles in anti-coagulation and normal hemostatic balance.¹⁸¹ Thus, their local delivery at vascular injury sites is attractive for the inhibition of thrombosis. Protein C is activated by thrombin–thrombomodulin complexes on intact endothelial cell surfaces, prompting anti-thrombotic activity. Foo et al. performed stent-based delivery of protein C in a balloon injury animal model using a stent coated with cellulose polymer and then immersed in buffer solution contain-




Figure 10. Schematic illustrations of multiple coated layers of releasable heparin complexes on implantable stents. Adapted from ref 195.

ing protein C for 60 min.¹⁶¹ Local delivery of protein C produced significant inhibition of thrombosis in a rabbit iliac artery model.

5. Polysaccharide Agents

Due partly to its extensive history in coating blood-contacting devices, the natural sulfated glycosaminoglycan anticoagulant, heparin, has been especially attractive as a stent coating, attempting to exploit its intrinsically high anti-coagulant activity through neutralization of thrombin by interaction with anti-thrombin III^{182,183} even in clinical trials with mixed results.^{183–186} In a great deal of such studies, heparin coating is achieved by covalent coupling of aldehyde groups created on heparin by mild oxidation (or under saccharide aldol equilibria) to amino groups attached on stents.^{182,183,185,187} Such covalent coupling produces a surface density and interaction between immobilized heparin and circulating antithrombin III. Heparin blending with other polymers as a coating produced a reduction of stent thrombosis.^{89,188} Recently, the combined use of heparin coating and injection of abciximab showed more effective activity against coagulation than a heparin-coated stent alone or abciximab alone.¹⁸⁹

However, it is likely that heparin delivery could have other cell-specific pharmacological effects. Heparin specifically inhibits a protein-kinase-C-dependent cell cycle pathway in SMCs.^{190,191} Moreover, it interacts with cell receptors, growth factors, and adhesion molecules, resulting in prevention of SMC migration and proliferation.¹⁹¹ As many of these activities require soluble heparin to bind cell receptors or penetrate intracellularly, binding of heparin to stents is unfavorable to exert any anti-proliferative activity. Thus, heparin's anti-proliferative activity was evaluated by local delivery to the injury site¹⁹² and compared with that of rapamycin.^{193,194} To achieve stent-based delivery of heparin, Matsumoto et al. created multilayers of heparin and cationic molecules via layered electrostatic interactions, as depicted in Figure 10.¹⁹⁵ Following in vivo stent implantation, immobilized heparin successfully released from the stent: Multilayer coating enabled not only slow heparin release but also control of heparin loading.

Because of its longer half-life, higher dosing possible, and extended bioavailability compared with unfractionated heparin (approximately 15 kDa), low-molecular-weight heparin (LMWH, ~2–9 kDa) is expected to provide more effective inhibition of restenosis than unfractionated heparin.^{196–198} Koromila et al. recently approached local LMWH delivery from a stent using liposomes to achieve significant LMWH delivery from a polyethylene terephthalate (PET)-coated stent by stent immersion into liposome solutions.¹⁹⁹ LMWH release from the stent was controllable, depending on liposome lipid composition and liposome type (dehydrated–rehydrated vesicles versus multilamellar vesicles). Combinations of LMWH and liposome encapsulation could be useful as a stent-based delivery system




Figure 11. (A and B) Endothelial progenitor cell (EPC)-seeded stents attached to a balloon catheter. (C and D) Fluorescence images of an EPC-seeded stent observed by nuclear staining of EPCs with Picogreen dye. Original magnification: (C) $\times 40$, (D) $\times 20$. Scale bar is 1 mm. Reprinted with permission from ref 214. Copyright 2003 Elsevier.

to prevent restenosis, avoiding known systemic LMWH problems (thrombocytopenia) with minimal, local doses.

Other types of polysaccharide could also be used for stent coating. Local delivery of hyaluronan (hyaluronic acid, HA) from a stent or coating on a stent inhibited platelet thrombus formation.^{200–202} Dextran is another polysaccharide that could act as an anti-platelet agent^{203,204} and also after chemical modification inhibit SMC proliferation as demonstrated by direct intraluminal injection at a stented site in rabbit iliac arteries.²⁰⁵ Fucoidan, a sulfated polysaccharide extracted from brown seaweed, also shows promise as a potent therapeutic agent.²⁰⁶ Some studies suggest differences in anti-proliferative activities between fucoidan and heparin (e.g., effects on mitogenesis induced by fetal calf serum and PDGF BB homodimer in human vascular SMCs). Thus, fucoidan in various molecular weight forms might prove to be a more anti-proliferative agent than heparin.^{207–209} Deux et al. reported inhibition of neointimal hyperplasia by intraluminal injection of LMW fucoidan to injury sites in iliac arteries.²¹⁰ This evidence supports the use of local delivery of LMW fucoidan from stents as a useful strategy against restenosis.

6. Cell-Based Therapies

Cell-based therapeutics represent a rapidly advancing technique to treat cardiovascular diseases.²¹¹ Nonetheless, cell sourcing and functional reliability remain issues that could delay the transition of cell therapy from an attractive experimental tool to a comprehensive therapeutic application. Ex vivo gene therapy is a common method to treat autologous cells with a transgene and then implant the transfected cells back into the host. This approach was used to produce a transfected SMC-coated stent with stable gene expression.²¹² In this study, plasmid DNA encoding GFP was transfected into SMCs, and the SMCs were then seeded onto a mesh stent. Using fibronectin for stent coating, a more than 20-fold increase in cell seeding was realized on the stent, compared to an uncoated stent. No evidence of SMC migration from the stent was detected, and stable gene expression was shown for 1 month after stent implantation.

As EPCs have an important role in endothelial repair and enhance re-endothelialization after vessel trauma in PTCA,^{172–174} EPCs were seeded onto a stent to accelerate re-endothelialization at the stented site by their migration and proliferation.^{213,214} An EPC–collagen hybrid material was formed by incubation of EPCs with collagen gel for 1 week. By insertion of a metal stent into this mixture, cell loading ($6.3 \pm 2.5 \times 10^5$ cells on 2

cm of stent) was achieved.²¹³ As shown in Figure 11, EPCs covered the stent surface. EPCs delivered from a gelatin-coated stent migrated from these seeded stents, forming an endothelialized luminal surface.²¹⁴ While EPC seeding on a stent promotes re-endothelialization, Aoki et al. immobilized anti-CD34 antibody specific to EPC cell surface markers onto a stent.²¹⁵ Captured cells from host circulation covered more than 90% of the stent surface 1 h after stent implantation, suggesting that EPC capture provides significant clinical feasibility against restenosis. Recently, to exert maximal potential, new materials were used to improve EC seeding on stent-based templates.²¹⁶ Cell-based approaches provide the benefits of autologous cell seeding or endogenous recruitment, combination therapies with stent-based drug delivery systems to suppress side effects, and possible alternative cell sourcing for stent coverage in the future. However, while EPCs comprise a significant fraction of circulating cells in animal models, EPCs represent a very small fraction of circulating cells in humans (e.g., less than 0.1%),^{217,218} and further development of this idea is required to demonstrate clinical potential.

7. Nanotechnology Approaches

Biodegradable nano- and microspheres enable controlled release of therapeutic drugs^{219,220} and can be combined within DES coatings with combinations of other drug forms. Potent anti-restenotic agents, tyrphostin compounds (AG-1295 or AGL-2043) encapsulated in PLA nanospheres were released in a size-dependent manner.^{221,222} In this regard, stent-based controlled release of anti-restenotic drugs such as angiostatin²²³ and NO donors⁵² formulated within PLGA microspheres was performed from DESs. Intraluminal delivery of AGL-2043 in PLA nanospheres decreased neointimal formation in rat carotid arteries in comparison to systemically administrated free AGL-2043.²²² Kolodgie et al. used nanospheres to stabilize the paclitaxel bioactivity in systemic parenteral dosing.²²⁴ Stabilization of protein drugs is particularly important in their controlled release because proteins easily lose bioactivities when formulated. Biodegradable nano- and microspheres are known to stabilize encapsulated proteins.^{177,178} Degradable poly(DL-lactide-co-glycolide) (PDLGA) microspheres containing albumin (66 kDa) as a model protein were loaded onto a PLLA stent by dipping in microsphere powders, and release was shown to depend on microsphere structure.²²⁵ Thus, nano- and microspheres may improve anti-restenotic effects of proteins and other biopharmaceutical drugs delivered locally from stents.

Nanoparticle surfaces can also be modified with various functional molecules, providing specific targeted, labeled, and long-circulating nanoparticles.²²⁶ For instance, tissue factor (TF)-targeted nanoparticles modified with anti-TF antibody specifically bind to SMC membranes in vivo. TF-modified perfluorocarbon nanoparticles containing paclitaxel delivered to cultured SMCs decreased cell proliferation compared to nontargeted nanoparticles.²²⁷ Iron oxide particles were used to magnetically localize ECs to stents.²²⁸ Endothelial outgrowth cells (EOCs) labeled with magnetic particles within their cytoplasm interacted with a magnetized stent and were captured on the stent surface. Following the stent implantation in pig coronary arteries, the EOCs labeled with the microspheres localized on the stented site.

8. Conclusions

A wide array of new, complex drug forms, primarily biopharmaceuticals comprising proteins, nucleic acids, and cell therapies, are emerging as attractive new cardiovascular thera-

peutic candidates with new, specific stent-based delivery requirements for DES applications. Many of these new drugs are substantially larger in size (molecular weights $\sim 10^3$ – 10^6 Da) than current drugs typically used on DES systems ($< 10^3$ Da). This means that large drug dosing within the DES coating or on surfaces will be even more limited than for current drugs because of these unusual drug sizes, physical chemistry, and stent loading restrictions. DES delivery of these new molecules will require new designs and extensive new stability and pharmacological analyses. Because of the unique targets and bioactivities of such biopharmaceuticals, improvements in desired anti-proliferative, anti-coagulant, pro-endothelialization, bio- and blood compatibility, and/or biodegradability are expected. Increased efficacy could also result from increased specificity and limited side effects, improving local pharmacology compared to current FDA-approved small-molecular-weight agents. However, it is likely that drugs alone will not solve all clinical stenting issues. Further DES developments will likely combine other emerging innovations in advanced therapeutics involving related new drug classes and cell therapies relevant to future DES delivery as well as implement new biomaterials, surgical, and stent design improvements. To bring these agents forward toward clinical use, creative approaches to formulating, testing, and understanding the mechanisms of action of these agents in the DES context is required. Randomized, blinded trials that assess stent clinical efficacy without bias in study designs will be required to fully assess performance enhancements.^{229,230}

Acknowledgment. This work was supported by a Research Fellowship from the Japan Society for Promotion of Science for Young Scientists (to H.T) and National Institutes of Health Grant No. EB00894 (to D.W.G.).

References and Notes

- (1) Hehrlein, C.; Arab, A.; Bode, C. *Basic Res. Cardiol.* **2002**, *97*, 417–423.
- (2) Fattori, R.; Piva, T. *Lancet* **2003**, *361*, 247–249.
- (3) Burt, H. M.; Hunter, W. L. *Adv. Drug Delivery Rev.* **2006**, *58*, 350–357.
- (4) Scott, N. A. *Adv. Drug Delivery Rev.* **2006**, *58*, 358–376.
- (5) Bennett, M. R.; O'Sullivan, M. *Pharmacol. Ther.* **2001**, *91*, 149–166.
- (6) Sousa, J. E.; Serruys, P. W.; Costa, M. A. *Circulation* **2003**, *107*, 2274–2279.
- (7) Kavanagh, C. A.; Rochev, Y. A.; Gallagher, W. A.; Dawson, K. A.; Keenan, A. K. *Pharmacol. Ther.* **2004**, *102*, 1–15.
- (8) Faxon, D. P. *Circulation* **2002**, *106*, 2296–2298.
- (9) Windecker, S.; Roffi, M.; Meier, B. *Curr. Pharm. Des.* **2003**, *9*, 1077–1094.
- (10) Koster, R.; Vieluf, D.; Kiehn, M.; Sommerauer, M.; Kahler, J.; Baldus, S.; Meinertz, T.; Hamm, C. W. *Lancet* **2000**, *356*, 1895–1897.
- (11) De Scheerder, I.; Szilard, M.; Yanming, H.; Ping, X. B.; Verbeken, E.; Neerincx, D.; Demeyere, E.; Coppens, W.; Van de Werf, F. J. *Invasive Cardiol.* **2000**, *12*, 389–394.
- (12) Gutensohn, K.; Beythien, C.; Bau, J.; Fenner, T.; Grewe, P.; Koester, R.; Padmanaban, K.; Kuehn, P. *Thromb. Res.* **2000**, *99*, 577–585.
- (13) Linder, S.; Pinkowski, W.; Aepfelbacher, M. *Biomaterials* **2002**, *23*, 767–773.
- (14) Monnick, S. H.; van Boven, A. J.; Peels, H. O.; Tigchelaar, I.; de Kam, P. J.; Crijns, H. J.; van Oeveren, W. J. *Invest. Med.* **1999**, *47*, 304–310.
- (15) Haase, J.; Störger, H.; Hofmann, M.; Schwarz, C. E.; Reinemer, H.; Schwarz, F. J. *Invasive Cardiol.* **2003**, *15*, 562–565.
- (16) Airolidi, F.; Colombo, A.; Tavano, D.; Stankovic, G.; Klugmann, S.; Paolillo, V.; Bonizzoni, E.; Briguori, C.; Carlino, M.; Montorfano, M.; Liistro, F.; Castelli, A.; Ferrari, A.; Sgura, F.; Di Mario, C. *Am. J. Cardiol.* **2004**, *93*, 474–477.
- (17) Colombo, A.; Airolidi, F. J. *Invasive Cardiol.* **2003**, *15*, 566–567.

- (18) Hiatt, B. L.; Ikeno, F.; Yeung, A. C.; Carter, A. J. *Catheter. Cardiovasc. Interv.* **2002**, *55*, 409–417.
- (19) Sousa, J. E.; Serruys, P. W.; Costa, M. A. *Circulation* **2003**, *107*, 2383–2389.
- (20) Carter, A. J. *Catheter. Cardiovasc. Interv.* **2005**, *66*, 496–498.
- (21) Moses, J. W.; Leon, M. B.; Popma, J. J.; Fitzgerald, P. J.; Holmes, D. R.; O'Shaughnessy, C.; Caputo, R. P.; Kereiakes, D. J.; Williams, D. O.; Teirstein, P. S.; Jaeger, J. L.; Kuntz, R. E. *N. Engl. J. Med.* **2003**, *349*, 1315–1323.
- (22) Stone, G. W.; Ellis, S. G.; Cannon, L.; Mann, J. T.; Greenberg, J. D.; Spriggs, D.; O'Shaughnessy, C. D.; DeMaio, S.; Hall, P.; Popma, J. J.; Koglin, J.; Russell, M. E. *JAMA, J. Am. Med. Assoc.* **2005**, *294*, 1215–1223.
- (23) Hong, M. K.; Mintz, G. S.; Lee, C. W.; Song, J. M.; Han, K. H.; Kang, D. H.; Song, J. K.; Kim, J. J.; Weissman, N. J.; Fearnot, N. E.; Park, S. W.; Park, S. J. *Circulation* **2003**, *107*, 517–520.
- (24) Gershlick, A.; De Scheerder, I.; Chevalier, B.; Stephens-Lloyd, A.; Camenzind, E.; Vrints, C.; Reifart, N.; Missault, L.; Goy, J. J.; Brinker, J. A.; Raizner, A. E.; Urban, P.; Heldman, A. W. *Circulation* **2004**, *109*, 487–493.
- (25) Halkin, A.; Stone, G. W. *J. Interv. Cardiol.* **2004**, *17*, 271–282.
- (26) Wessely, R.; Schomig, A.; Kastrati, A. *J. Am. Coll. Cardiol.* **2006**, *47*, 708–714.
- (27) Costa, R. A.; Lansky, A. J.; Mintz, G. S.; Mehran, R.; Tsuchiya, Y.; Negoita, M.; Gilutz, Y.; Nikolsky, E.; Fahy, M.; Pop, R.; Cristea, E.; Carlier, S.; Dangas, G.; Stone, G. W.; Leon, M. B.; Muller, R.; Techen, G.; Grube, E. *Am. J. Cardiol.* **2005**, *95*, 113–116.
- (28) Fajadet, J.; Wijns, W.; Laarman, G. J.; Kuck, K. H.; Ormiston, J.; Munzel, T.; Popma, J. J.; Fitzgerald, P. J.; Bonan, R.; Kuntz, R. E. *Circulation* **2006**, *114*, 798–806.
- (29) Kandzari, D. E.; Leon, M. B. *J. Interv. Cardiol.* **2006**, *19*, 405–413.
- (30) Hofma, S. H.; van der Giessen, W. J.; van Dalen, B. M.; Lemos, P. A.; McFadden, E. P.; Sianos, G.; Ligthart, J. M.; van Esen, D.; de Feyter, P. J.; Serruys, P. W. *Eur. Heart J.* **2006**, *27*, 166–170.
- (31) Oyabu, J.; Ueda, Y.; Ogasawara, N.; Okada, K.; Hirayama, A.; Kodama, K. *Am. Heart J.* **2006**, *152*, 1168–1174.
- (32) Lang, N. N.; Newby, D. E. *Arterioscler., Thromb., Vasc. Biol.* **2007**, *27*, 261–262.
- (33) Muldowney, J. A., 3rd; Stringham, J. R.; Levy, S. E.; Gleaves, L. A.; Eren, M.; Piana, R. N.; Vaughan, D. E. *Arterioscler., Thromb., Vasc. Biol.* **2007**, *27*, 400–406.
- (34) Moussa, I.; Leon, M. B.; Baim, D. S.; O'Neill, W. W.; Popma, J. J.; Buchbinder, M.; Midwall, J.; Simonton, C. A.; Keim, E.; Wang, P.; Kuntz, R. E.; Moses, J. W. *Circulation* **2004**, *109*, 2273–2278.
- (35) de Araujo Goncalves, P.; Seabra-Gomes, R.; Teles, R.; Almeida, M.; Aguiar, C.; Raposo, L.; Ferreira, J.; Pereira Machado, F. *Heart* **2006**, *92*, 1155–1156.
- (36) Jimenez-Quevedo, P.; Sabate, M.; Angiolillo, D. J.; Costa, M. A.; Alfonso, F.; Gomez-Hospital, J. A.; Hernandez-Antolin, R.; Banuelos, C.; Goicolea, J.; Fernandez-Aviles, F.; Bass, T.; Escaned, J.; Moreno, R.; Fernandez, C.; Macaya, C. *J. Am. Coll. Cardiol.* **2006**, *47*, 2172–2179.
- (37) Agostoni, P.; Biondi-Zoccai, G. G.; Gasparini, G. L.; Anselmi, M.; Morando, G.; Turri, M.; Abbate, A.; McFadden, E. P.; Vassanelli, C.; Zardini, P.; Colombo, A.; Serruys, P. W. *Eur. Heart J.* **2005**, *26*, 881–889.
- (38) Colombo, A.; Moses, J. W.; Morice, M. C.; Ludwig, J.; Holmes, D. R., Jr.; Spanos, V.; Louvard, Y.; Desmedt, B.; Di Mario, C.; Leon, M. B. *Circulation* **2004**, *109*, 1244–1249.
- (39) Sharma, S. K. *Catheter. Cardiovasc. Interv.* **2005**, *65*, 10–16.
- (40) Ge, L.; Tsagalou, E.; Iakovou, I.; Sangiorgi, G. M.; Corvaja, N.; Airolidi, F.; Chieffo, A.; Montorfano, M.; Michev, I.; Colombo, A. *Am. J. Cardiol.* **2005**, *95*, 757–760.
- (41) Schainfeld, R. M. *Catheter. Cardiovasc. Interv.* **2002**, *56*, 421–431.
- (42) Krueger, K. D.; Mitra, A. K.; DelCore, M. G.; Hunter, W. J., III; Agrawal, D. K. *J. Clin. Pathol.* **2006**, *59*, 575–579.
- (43) Machan, L. *Adv. Drug Delivery Rev.* **2006**, *58*, 447–462.
- (44) Liu, X.; Huang, Y.; Hanet, C.; Vandormael, M.; Legrand, V.; Dens, J.; Vandenbossche, J. L.; Missault, L.; Vrints, C.; De Scheerder, I. *Catheter. Cardiovasc. Interv.* **2003**, *60*, 172–178.
- (45) Serruys, P. W.; Ormiston, J. A.; Sianos, G.; Sousa, J. E.; Grube, E.; den Heijer, P.; de Feyter, P.; Buszman, P.; Schomig, A.; Marco, J.; Polonski, L.; Thuesen, L.; Zeiher, A. M.; Bett, J. H.; Suttrop, M. J.; Glogar, H. D.; Pitney, M.; Wilkins, G. T.; Whitbourn, R.; Veldhof, S.; Miquel, K.; Johnson, R.; Coleman, L.; Virmani, R. *J. Am. Coll. Cardiol.* **2004**, *44*, 1363–1367.
- (46) Sarkar, R.; Meinberg, E. G.; Stanley, J. C.; Gordon, D.; Webb, R. C. *Circ. Res.* **1996**, *78*, 225–230.
- (47) Rizvi, M. A.; Myers, P. R. *J. Mol. Cell. Cardiol.* **1997**, *29*, 1779–1789.
- (48) Guo, J. P.; Milhoan, K. A.; Tuan, R. S.; Lefer, A. M. *Circ. Res.* **1994**, *75*, 77–84.
- (49) Matsuno, H.; Stassen, J. M.; Vermeylen, J.; Deckmyn, H. *Circulation* **1994**, *90*, 2203–2206.
- (50) Langeveld, B.; van Gilst, W. H.; Tio, R. A.; Zijlstra, F.; Roks, A. J. *Hypertension* **2005**, *45*, 138–141.
- (51) Grant, M. B.; Wargovich, T. J.; Ellis, E. A.; Caballero, S.; Mansour, M.; Pepine, C. J. *Circulation* **1994**, *89*, 1511–1517.
- (52) Do, Y. S.; Kao, E. Y.; Ganaha, F.; Minamiguchi, H.; Sugimoto, K.; Lee, J.; Elkins, C. J.; Amabile, P. G.; Kuo, M. D.; Wang, D. S.; Waugh, J. M.; Dake, M. D. *Radiology* **2004**, *230*, 377–382.
- (53) Masters, K. S. B.; Lipke, E. A.; Rice, E. E. H.; Liel, M. S.; Myler, H. A.; Zygourakis, C.; Tulis, D. A.; West, J. L. *J. Biomater. Sci., Polym. Ed.* **2005**, *16*, 659–672.
- (54) Kwok, O. H.; Chow, W. H.; Law, T. C.; Chiu, A.; Ng, W.; Lam, W. F.; Hong, M. K.; Popma, J. J. *Catheter. Cardiovasc. Interv.* **2005**, *66*, 541–546.
- (55) Blindt, R.; Vogt, F.; Astafieva, I.; Fach, C.; Hristov, M.; Krott, N.; Seitz, B.; Kapurmiotu, A.; Kwok, C.; Dewor, M.; Bosserhoff, A. K.; Bernhagen, J.; Hanrath, P.; Hoffmann, R.; Weber, C. *J. Am. Coll. Cardiol.* **2006**, *47*, 1786–1795.
- (56) Salu, K. J.; Bosmans, J. M.; Huang, Y.; Hendriks, M.; Verhoeven, M.; Levels, A.; Cooper, S.; De Scheerder, I. K.; Vrints, C. J.; Bult, H. *Cardiovasc. Res.* **2006**, *69*, 536–544.
- (57) Wienieke, H.; Dirsch, O.; Sawitowski, T.; Gu, Y. L.; Brauer, H.; Dahmen, U.; Fischer, A.; Wnendt, S.; Erbel, R. *Catheter. Cardiovasc. Interv.* **2003**, *60*, 399–407.
- (58) Kollum, M.; Farb, A.; Schreiber, R.; Terfera, K.; Arab, A.; Geist, A.; Haberstroh, J.; Wnendt, S.; Virmani, R.; Hehrlein, C. *Catheter. Cardiovasc. Interv.* **2005**, *64*, 85–90.
- (59) Patti, G.; Chello, M.; Pasceri, V.; Colonna, D.; Carminati, P.; Covino, E.; Di Germano, S. *Clin. Ther.* **2005**, *27*, 1411–1419.
- (60) Abizaid, A.; Albertal, M.; Costa, M. A.; Abizaid, A. S.; Staico, R.; Feres, F.; Mattos, L. A.; Sousa, A. G.; Moses, J.; Kipshidize, N.; Roubin, G. S.; Mehran, R.; New, G.; Leon, M. B.; Sousa, J. E. *J. Am. Coll. Cardiol.* **2004**, *43*, 1118–1121.
- (61) Airolidi, F.; Di Mario, C.; Ribichini, F.; Presbitero, P.; Sganzerla, P.; Ferrero, V.; Vassanelli, C.; Briguori, C.; Carlino, M.; Montorfano, M.; Biondi-Zoccai, G. G.; Chieffo, A.; Ferrari, A.; Colombo, A. *Am. J. Cardiol.* **2005**, *96*, 664–667.
- (62) *Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics*; Mahato, R. I., Kim, S. W., Eds.; Taylor & Francis: London, 2002.
- (63) Sharif, F.; Daly, K.; Crowley, J.; O'Brien, T. *Cardiovasc. Res.* **2004**, *64*, 208–216.
- (64) Gruchala, M.; Roy, H.; Bhardwaj, S.; Yla-Herttuala, S. *Curr. Pharm. Des.* **2004**, *10*, 407–423.
- (65) Labhasetwar, V.; Chen, B. R.; Muller, D. W. M.; Bonadio, J.; Ciftci, K.; March, K.; Levy, R. J. *Adv. Drug Delivery Rev.* **1997**, *24*, 109–120.
- (66) Kornowski, R.; Fuchs, S. *Int. J. Cardiovasc. Interv.* **2000**, *3*, 67–70.
- (67) Brewster, L. P.; Brey, E. M.; Greisler, H. P. *Adv. Drug Delivery Rev.* **2006**, *58*, 604–629.
- (68) Peng, T.; Gibula, P.; Yao, K. D.; Goosen, M. F. A. *Biomaterials* **1996**, *17*, 685–694.
- (69) Eberhart, R. C.; Su, S. H.; Nguyen, K. T.; Zilberman, M.; Tang, L. P.; Nelson, K. D.; Frenkel, P. J. *Biomater. Sci., Polym. Ed.* **2003**, *14*, 299–312.
- (70) Zilberman, M.; Nelson, K. D.; Eberhart, R. C. *J. Biomed. Mater. Res., Part B* **2005**, *74*, 792–799.
- (71) Luo, D.; Woodrow-Mumford, K.; Belcheva, N.; Saltzman, W. M. *Pharm. Res.* **1999**, *16*, 1300–1308.
- (72) Park, T. G.; Jeong, J. H.; Kim, S. W. *Adv. Drug Delivery Rev.* **2006**, *58*, 467–486.
- (73) Klugherz, B. D.; Jones, P. L.; Cui, X. M.; Chen, W. L.; Meneveau, N. F.; DeFelice, S.; Connolly, J.; Wilensky, R. L.; Levy, R. J. *Nat. Biotechnol.* **2000**, *18*, 1181–1184.
- (74) Takahashi, A.; Palmer-Opolski, M.; Smith, R. C.; Walsh, K. *Gene Ther.* **2003**, *10*, 1471–1478.
- (75) Niidome, T.; Huang, L. *Gene Ther.* **2002**, *9*, 1647–1652.
- (76) Verma, I. M.; Weitzman, M. D. *Annu. Rev. Biochem.* **2005**, *74*, 711–738.
- (77) Muhs, A.; Heublein, B.; Schletter, J.; Herrmann, A.; Rudiger, M.; Sturm, M.; Grust, A.; Malms, J.; Schrader, J.; Von der Leyen, H. E. *Hum. Gene Ther.* **2003**, *14*, 375–383.

- (78) Vonderleyen, H. E.; Gibbons, G. H.; Morishita, R.; Lewis, N. P.; Zhang, L.; Nakajima, M.; Kaneda, Y.; Cooke, J. P.; Dzau, V. J. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 1137–1141.
- (79) Wang, K.; Kessler, P. D.; Zhou, Z. M.; Penn, M. S.; Forudi, F.; Zhou, X. R.; Tarakji, K.; Kibbe, M.; Kovacs, I.; Brough, D. E.; Topol, E. J.; Lincoff, A. M. *Mol. Ther.* **2003**, *7*, 597–603.
- (80) Turunen, M. P.; Hiltunen, M. O.; Ruponen, M.; Virkamaki, L.; Szoka, F. C., Jr.; Urtti, A.; Yla-Herttuala, S. *Gene Ther.* **1999**, *6*, 6–11.
- (81) Jewell, C. M.; Zhang, J. T.; Fredin, N. J.; Wolff, M. R.; Hacker, T. A.; Lynn, D. M. *Biomacromolecules* **2006**, *7*, 2483–2491.
- (82) Kay, M. A.; Glorioso, J. C.; Naldini, L. *Nat. Med.* **2001**, *7*, 33–40.
- (83) Carter, B. J. *Hum. Gene Ther.* **2005**, *16*, 541–550.
- (84) Mano, T.; Luo, Z. Y.; Sahara, T.; Smith, R. C.; Esser, S.; Walsh, K. *Hum. Gene Ther.* **2000**, *11*, 1625–1635.
- (85) Huang, J.; Niu, X. L.; Phipps, A. M.; Annex, B. H.; Kontos, C. D. *Arterioscler., Thromb., Vasc. Biol.* **2005**, *25*, 354–358.
- (86) Ye, Y. W.; Landau, C.; Willard, J. E.; Rajasubramanian, G.; Moskowitz, A.; Aziz, S.; Meidell, R. S.; Eberhart, R. C. *Ann. Biomed. Eng.* **1998**, *26*, 398–408.
- (87) Chen, M. C.; Liang, H. F.; Chiu, Y. L.; Chang, Y.; Wei, H. J.; Sung, H. W. *J. Controlled Release* **2005**, *108*, 178–189.
- (88) Ho, H. O.; Lin, L. H.; Sheu, M. T. *J. Controlled Release* **1997**, *44*, 103–112.
- (89) Wissink, M. J. B.; Beernink, R.; Scharenborg, N. M.; Poot, A. A.; Engbers, G. H. M.; Beugeling, T.; van Aken, W. G.; Feijen, J. *J. Controlled Release* **2000**, *67*, 141–155.
- (90) Cloft, H. J.; Kallmes, D. F.; Lin, H. B.; Li, S. T.; Marx, W. F.; Hudson, S. B.; Helm, G. A.; Lopes, M. B.; McGraw, J. K.; Dion, J. E.; Jensen, M. E. *Radiology* **2000**, *214*, 557–562.
- (91) Klugherz, B. D.; Song, C. X.; Defelice, S.; Cui, X. M.; Lu, Z. B.; Connolly, J.; Hinson, J. T.; Wilensky, R. L.; Levy, R. J. *Hum. Gene Ther.* **2002**, *13*, 443–454.
- (92) Abrahams, J. M.; Song, C. X.; DeFelice, S.; Grady, M. S.; Diamond, S. L.; Levy, R. J. *Stroke* **2002**, *33*, 1376–1382.
- (93) Fishbein, I.; Stachelek, S. J.; Connolly, J. M.; Wilensky, R. L.; Alferiev, I.; Levy, R. J. *J. Controlled Release* **2005**, *109*, 37–48.
- (94) Perlstein, I.; Connolly, J. M.; Cui, X.; Song, C.; Li, Q.; Jones, P. L.; Lu, Z.; DeFelice, S.; Klugherz, B.; Wilensky, R.; Levy, R. J. *Gene Ther.* **2003**, *10*, 1420–1428.
- (95) Yamamoto, M.; Yamato, M.; Aoyagi, M.; Yamamoto, K. *Exp. Cell Res.* **1995**, *219*, 249–256.
- (96) Jones, P. L.; Jones, F. S.; Zhou, B.; Rabinovitch, M. *J. Cell Sci.* **1999**, *112*, 435–445.
- (97) van der Giessen, W. J.; Lincoff, A. M.; Schwartz, R. S.; van Beusekom, H. M. M.; Serruys, P. W.; Holmes, D. R.; Ellis, S. G.; Topol, E. J. *Circulation* **1996**, *94*, 1690–1697.
- (98) Carter, A. J.; Aggarwal, M.; Kopia, G. A.; Tio, F.; Tsao, P. S.; Kolata, R.; Yeung, A. C.; Llanos, G.; Dooley, L.; Falotico, R. *Cardiovasc. Res.* **2004**, *63*, 617–624.
- (99) Virmani, R.; Guagliumi, G.; Farb, A.; Musumeci, G.; Grieco, N.; Motta, T.; Mihalcsik, L.; Tespili, M.; Valsecchi, O.; Kolodgie, F. D. *Circulation* **2004**, *109*, 701–705.
- (100) McFadden, E. P.; Stabile, E.; Regar, E.; Cheneau, E.; Ong, A. T.; Kinnaird, T.; Suddath, W. O.; Weissman, N. J.; Torguson, R.; Kent, K. M.; Pichard, A. D.; Satler, L. F.; Waksman, R.; Serruys, P. W. *Lancet* **2004**, *364*, 1519–1521.
- (101) Joner, M.; Finn, A. V.; Farb, A.; Mont, E. K.; Kolodgie, F. D.; Ladich, E.; Kutys, R.; Skoric, K.; Gold, H. K.; Virmani, R. *J. Am. Coll. Cardiol.* **2006**, *48*, 193–202.
- (102) FDA Statement on Coronary Drug-Eluting Stents. <http://www.fda.gov/cdrh/news/091406.html> (accessed May 6, 2007).
- (103) Wessely, R.; Hausleiter, J.; Michaelis, C.; Jaschke, B.; Vogeser, M.; Milz, S.; Behnisch, B.; Schratzenstaller, T.; Renke-Gluszko, M.; Stover, M.; Wintermantel, E.; Kastrati, A.; Schomig, A. *Arterioscler., Thromb., Vasc. Biol.* **2005**, *25*, 748–753.
- (104) Hausleiter, J.; Kastrati, A.; Wessely, R.; Dibra, A.; Mehilli, J.; Schratzenstaller, T.; Graf, I.; Renke-Gluszko, M.; Behnisch, B.; Dirschinger, J.; Wintermantel, E.; Schomig, A. *Eur. Heart J.* **2005**, *26*, 1475–1481.
- (105) Fishbein, I.; Alferiev, I. S.; Nyanguile, O.; Gaster, R.; Vohs, J. M.; Wong, G. S.; Felderman, H.; Chen, I. W.; Choi, H.; Wilensky, R. L.; Levy, R. J. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 159–164.
- (106) Van Alsten, J. G. *Langmuir* **1999**, *15*, 7605–7614.
- (107) Man, S. P.; Motevalli, M.; Gardiner, S.; Sullivan, A.; Wilson, J. *Polyhedron* **2006**, *25*, 1017–1032.
- (108) Lewis, A. L. *Colloids Surf., B* **2000**, *18*, 261–275.
- (109) Lewis, A. L.; Tolhurst, L. A.; Stratford, P. W. *Biomaterials* **2002**, *23*, 1697–1706.
- (110) Whelan, D. M.; van der Giessen, W. J.; Krabbendam, S. C.; van Vliet, E. A.; Verdouw, P. D.; Serruys, P. W.; van Beusekom, H. M. *Heart* **2000**, *83*, 338–345.
- (111) Lewis, A. L.; Vick, T. A.; Collias, A. C. M.; Hughes, L. G.; Palmer, R. R.; Leppard, S. W.; Furze, J. D.; Taylor, A. S.; Stratford, P. W. *J. Mater. Sci.: Mater. Med.* **2001**, *12*, 865–870.
- (112) Anis, R. R.; Karsch, K. R. *Heart* **2006**, *92*, 585–588.
- (113) Walter, D. H.; Cejna, M.; Diaz-Sandoval, L.; Willis, S.; Kirkwood, L.; Stratford, P. W.; Tietz, A. B.; Kirchmair, R.; Silver, M.; Curry, C.; Wecker, A.; Yoon, Y. S.; Heidenreich, R.; Hanley, A.; Kearney, M.; Tio, F. O.; Kuenzler, P.; Isner, J. M.; Losordo, D. W. *Circulation* **2004**, *110*, 36–45.
- (114) Asahara, T.; Bauters, C.; Pastore, C.; Kearney, M.; Rossow, S.; Bunting, S.; Ferrara, N.; Symes, J. F.; Isner, J. M. *Circulation* **1995**, *91*, 2793–2801.
- (115) Van Belle, E.; Maillard, L.; Tio, F. O.; Isner, J. M. *Biochem. Biophys. Res. Commun.* **1997**, *235*, 311–316.
- (116) Van Belle, E.; Tio, F. O.; Chen, D. H.; Maillard, L.; Chen, D. F.; Kearney, M.; Isner, J. M. *J. Am. Coll. Cardiol.* **1997**, *29*, 1371–1379.
- (117) Laitinen, M.; Hartikainen, J.; Hiltunen, M. O.; Eranen, J.; Kiviniemi, M.; Narvanen, O.; Makinen, K.; Manninen, H.; Syvanne, M.; Martin, J. F.; Laakso, M.; Yla-Herttuala, S. *Hum. Gene Ther.* **2000**, *11*, 263–270.
- (118) Forough, R.; Koyama, N.; Hasenstab, D.; Lea, H.; Clowes, M.; Nikkari, S. T.; Clowes, A. W. *Circ. Res.* **1996**, *79*, 812–820.
- (119) Dollery, C. M.; Humphries, S. E.; McClelland, A.; Latchman, D. S.; McEwan, J. R. *Circulation* **1999**, *99*, 3199–3205.
- (120) Baker, A. H.; Zaltsman, A. B.; George, S. J.; Newby, A. C. *J. Clin. Invest.* **1998**, *101*, 1478–1487.
- (121) George, S. J.; Lloyd, C. T.; Angelini, G. D.; Newby, A. C.; Baker, A. H. *Circulation* **2000**, *101*, 296–304.
- (122) Johnson, T. W.; Wu, Y. X.; Herdeg, C.; Baumbach, A.; Newby, A. C.; Karsch, K. R.; Oberhoff, M. *Arterioscler., Thromb., Vasc. Biol.* **2005**, *25*, 754–759.
- (123) Sharif, F.; Hynes, S. O.; McMahon, J.; Cooney, R.; Conroy, S.; Dockery, P.; Duffy, G.; Daly, K.; Crowley, J.; Bartlett, J. S.; O'Brien, T. *Hum. Gene Ther.* **2006**, *17*, 741–750.
- (124) Davidson, B. L.; Stein, C. S.; Heth, J. A.; Martins, I.; Kotin, R. M.; Derksen, T. A.; Zabner, J.; Ghodsi, A.; Chiorini, J. A. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 3428–3432.
- (125) Yamauchi, F.; Koyamatsu, Y.; Kato, K.; Iwata, H. *Biomaterials* **2006**, *27*, 3497–3504.
- (126) Zhang, J.; Chua, L. S.; Lynn, D. M. *Langmuir* **2004**, *20*, 8015–8021.
- (127) Ren, K. F.; Ji, J.; Shen, J. C. *Bioconjugate Chem.* **2006**, *17*, 77–83.
- (128) Ren, K. F.; Ji, J.; Shen, J. C. *Biomaterials* **2006**, *27*, 1152–1159.
- (129) Nakayama, Y.; Matsuda, T. *J. Biomed. Mater. Res.* **1999**, *48*, 511–521.
- (130) Nakayama, Y.; Ji-Youn, K.; Nishi, S.; Ueno, H.; Matsuda, T. *J. Biomed. Mater. Res.* **2001**, *57*, 559–566.
- (131) Okino, H.; Nakayama, Y.; Tanaka, M.; Matsuda, T. *J. Biomed. Mater. Res.* **2002**, *59*, 233–245.
- (132) Akhtar, S.; Hughes, M. D.; Khan, A.; Bibby, M.; Hussain, M.; Nawaz, Q.; Double, J.; Sayyed, P. *Adv. Drug Delivery Rev.* **2000**, *44*, 3–21.
- (133) Pan, W. H.; Clawson, G. A. *J. Cell. Biochem.* **2006**, *98*, 14–35.
- (134) Morishita, R.; Gibbons, G. H.; Ellison, K. E.; Nakajima, M.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, V. J. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 8474–8478.
- (135) Fisher, M.; Liu, B.; Glennon, P. E.; Southgate, K. M.; Sale, E. M.; Sale, G. J.; Lewis, M. J.; Groves, P. H. *Atherosclerosis* **2001**, *156*, 289–295.
- (136) Lowe, H. C.; Fahmy, R. G.; Kavurma, M. M.; Baker, A.; Chesterman, C. N.; Khachigian, L. M. *Circ. Res.* **2001**, *89*, 670–677.
- (137) Gunn, J.; Holt, C. M.; Francis, S. E.; Shepherd, L.; Grohmann, M.; Newman, C. M.; Crossman, D. C.; Cumberland, D. C. *Circ. Res.* **1997**, *80*, 520–531.
- (138) Hayashi, K.; Banno, H.; Kadomatsu, K.; Takei, Y.; Komori, K.; Muramatsu, T. *Am. J. Physiol.: Heart Circ. Physiol.* **2005**, *288*, H2203–H2209.
- (139) Li, Y.; Fukuda, N.; Kunitomo, S.; Yokoyama, S.; Hagikura, K.; Kawano, T.; Takayama, T.; Honye, J.; Kobayashi, N.; Mugishima, H.; Saito, S.; Serie, K. *J. Cardiovasc. Pharmacol.* **2006**, *48*, 184–190.
- (140) Shi, Y.; Fard, A.; Galeo, A.; Hutchinson, H. G.; Vermani, P.; Dodge, G. R.; Hall, D. J.; Shaheen, F.; Zalewski, A. *Circulation* **1994**, *90*, 944–951.
- (141) Zhang, X. X.; Cui, C. C.; Xu, X. G.; Hu, X. S.; Fang, W. H.; Kuang, B. J. *Chin. Med. J. (Beijing, China, Engl. Ed.)* **2004**, *117*, 258–263.

- (142) Kutryk, M. J.; Foley, D. P.; van den Brand, M.; Hamburger, J. N.; van der Giessen, W. J.; deFeyter, P. J.; Bruining, N.; Sabate, M.; Serruys, P. W. *J. Am. Coll. Cardiol.* **2002**, *39*, 281–287.
- (143) Kipshidze, N.; Keane, E.; Stein, D.; Chawla, P.; Skriniska, V.; Shankar, L. R.; Khanna, A.; Komorowski, R.; Haudenschild, C.; Iversen, P.; Leon, M. B.; Keelan, M. H.; Moses, J. *Catheter. Cardiovasc. Interv.* **2001**, *54*, 247–256.
- (144) Kipshidze, N. N.; Kim, H. S.; Iversen, P.; Yazdi, H. A.; Bhargava, B.; New, G.; Mehran, R.; Tio, F.; Haudenschild, C.; Dangas, G.; Stone, G. W.; Iyer, S.; Roubin, G. S.; Leon, M. B.; Moses, J. W. *J. Am. Coll. Cardiol.* **2002**, *39*, 1686–1691.
- (145) Kipshidze, N. N.; Iversen, P.; Kim, H. S.; Yazdi, H.; Dangas, G.; Seaborn, R.; New, G.; Tio, F.; Waksman, R.; Mehran, R.; Tsapenko, M.; Stone, G. W.; Roubin, G. S.; Iyer, S.; Leon, M. B.; Moses, J. W. *Catheter. Cardiovasc. Interv.* **2004**, *61*, 518–527.
- (146) Summerton, J. *Biochim. Biophys. Acta* **1999**, *1489*, 141–158.
- (147) Zhang, Z. Q.; Cao, X. C.; Zhao, X. B.; Withers, S. B.; Holt, C. M.; Lewis, A. L.; Lu, J. R. *Biomacromolecules* **2006**, *7*, 784–791.
- (148) Chan, K. H.; Armstrong, J.; Withers, S.; Malik, N.; Cumberland, D. C.; Gunn, J.; Holt, C. M. *Biomaterials* **2007**, *28*, 1218–1224.
- (149) Lewis, A. L.; Cumming, Z. L.; Goreish, H. H.; Kirkwood, L. C.; Tolhurst, L. A.; Stratford, P. W. *Biomaterials* **2001**, *22*, 99–111.
- (150) Lewis, A. L.; Berwick, J.; Davies, M. C.; Roberts, C. J.; Wang, J. H.; Small, S.; Dunn, A.; O'Byrne, V.; Redman, R. P.; Jones, S. A. *Biomaterials* **2004**, *25*, 3099–3108.
- (151) Tomita, N.; Azuma, H.; Kaneda, Y.; Ogihara, T.; Morishita, R. *Curr. Drug Targets* **2003**, *4*, 339–346.
- (152) Kitamoto, S.; Egashira, K.; Kataoka, C.; Koyanagi, M.; Katoh, M.; Shimokawa, H.; Morishita, R.; Kaneda, Y.; Sueishi, K.; Takeshita, A. *Circulation* **2000**, *102*, 806–812.
- (153) Yoshimura, S.; Morishita, R.; Hayashi, K.; Yamamoto, K.; Nakagami, H.; Kaneda, Y.; Sakai, N.; Ogihara, T. *Gene Ther.* **2001**, *8*, 1635–1642.
- (154) Suzuki, J.; Ito, H.; Gotoh, R.; Morishita, R.; Egashira, K.; Isobe, M. *Circ. J.* **2004**, *68*, 270–271.
- (155) Kalinowski, M.; Viehofer, K.; Hamann, C.; Barry, J. J.; Kleb, B.; Klose, K. J.; Wagner, H. J.; Alfke, H. *Cardiovasc. Interv. Radiol.* **2005**, *28*, 331–337.
- (156) Radke, P. W.; Griesenbach, U.; Kivela, A.; Vick, T.; Judd, D.; Munkonge, F.; Willis, S.; Geddes, D. M.; Yla-Herttuala, S.; Alton, E. W. *Hum. Gene Ther.* **2005**, *16*, 734–740.
- (157) Ohtani, K.; Egashira, K.; Nakano, K.; Zhao, G.; Funakoshi, K.; Ihara, Y.; Kimura, S.; Tominaga, R.; Morishita, R.; Sunagawa, K. *Circulation* **2006**, *114*, 2773–2779.
- (158) Jovinge, S.; Hultgardh-Nilsson, A.; Regnstrom, J.; Nilsson, J. *Arterioscler., Thromb., Vasc. Biol.* **1997**, *17*, 490–497.
- (159) Clausell, N.; Molossi, S.; Sett, S.; Rabinovitch, M. *Circulation* **1994**, *89*, 2768–2779.
- (160) Javed, Q.; Swanson, N.; Vohra, H.; Thurston, H.; Gershlick, A. H. *Exp. Mol. Pathol.* **2002**, *73*, 104–111.
- (161) Foo, R. S.; Gershlick, A. H.; Hogrefe, K.; Baron, J. H.; Johnston, T. W.; Hussey, A. J.; Garner, I.; de Bono, D. P. *Thromb. Haemostasis* **2000**, *83*, 496–502.
- (162) Grainger, D. W. *Expert Opin. Biol. Ther.* **2004**, *4*, 1029–1044.
- (163) Lefkovits, J.; Plow, E. F.; Topol, E. J. *N. Engl. J. Med.* **1995**, *332*, 1553–1559.
- (164) Azrin, M. A.; Ling, F. S.; Chen, Q.; Pawashe, A.; Migliaccio, F.; Homer, R.; Todd, M.; Ezekowitz, M. D. *Circ. Res.* **1994**, *75*, 268–277.
- (165) Aggarwal, R. K.; Ireland, D. C.; Azrin, M. A.; Ezekowitz, M. D.; de Bono, D. P.; Gershlick, A. H. *Circulation* **1996**, *94*, 3311–3317.
- (166) Tam, S. H.; Sassoli, P. M.; Jordan, R. E.; Nakada, M. T. *Circulation* **1998**, *98*, 1085–1091.
- (167) Valgimigli, M.; Percoco, G.; Malagutti, P.; Campo, G.; Ferrari, F.; Barbieri, D.; Cicchitelli, G.; McFadden, E. P.; Merlini, F.; Ansani, L.; Guardigli, G.; Bettini, A.; Parinello, G.; Boersma, E.; Ferrari, R. *JAMA, J. Am. Med. Assoc.* **2005**, *293*, 2109–2117.
- (168) The ERASER Investigators *Circulation* **1999**, *100*, 799–806.
- (169) Baron, J. H.; Gershlick, A. H.; Hogrefe, K.; Armstrong, J.; Holt, C. M.; Aggarwal, R. K.; Azrin, M.; Ezekowitz, M.; de Bono, D. P. *Cardiovasc. Res.* **2000**, *46*, 585–594.
- (170) Hong, Y. J.; Jeong, M. H.; Kim, W.; Lim, S. Y.; Lee, S. H.; Hong, S. N.; Kim, J. H.; Ahn, Y. K.; Cho, J. G.; Park, J. C.; Cho, D. L.; Kim, H.; Kang, J. C. *Am. J. Cardiol.* **2004**, *94*, 1050–1054.
- (171) Kim, W.; Jeong, M. H.; Kim, K. H.; Sohn, I. S.; Hong, Y. J.; Park, H. W.; Kim, J. H.; Ahn, Y. K.; Cho, J. G.; Park, J. C.; Cho, D. L.; Kang, J. C. *J. Am. Coll. Cardiol.* **2006**, *47*, 933–938.
- (172) Melo, L. G.; Gneccchi, M.; Pachori, A. S.; Kong, D.; Wang, K.; Liu, X.; Pratt, R. E.; Dzau, V. J. *Arterioscler., Thromb., Vasc. Biol.* **2004**, *24*, 1761–1774.
- (173) Kong, D.; Melo, L. G.; Mangi, A. A.; Zhang, L.; Lopez-Illasaca, M.; Perrella, M. A.; Liew, C. C.; Pratt, R. E.; Dzau, V. J. *Circulation* **2004**, *109*, 1769–1775.
- (174) Werner, N.; Nickenig, G. *J. Cell. Mol. Med.* **2006**, *10*, 318–332.
- (175) Conklin, B. S.; Wu, H.; Lin, P. H.; Lumsden, A. B.; Chen, C. *Artif. Organs* **2004**, *28*, 668–675.
- (176) Swanson, N.; Hogrefe, K.; Javed, Q.; Gershlick, A. H. *Int. J. Cardiol.* **2003**, *92*, 265–269.
- (177) Zhu, G.; Mallery, S. R.; Schwendeman, S. P. *Nat. Biotechnol.* **2000**, *18*, 52–57.
- (178) Jiang, W.; Schwendeman, S. P. *Pharm. Res.* **2001**, *18*, 878–885.
- (179) Kavanagh, C. A.; Gorelova, T. A.; Selezneva, I. I.; Rochev, Y. A.; Dawson, K. A.; Gallagher, W. M.; Gorelov, A. V.; Keenan, A. K. *J. Biomed. Mater. Res., Part A* **2005**, *72*, 25–35.
- (180) Ehrbar, M.; Djonov, V. G.; Schnell, C.; Tschanz, S. A.; Martiny-Baron, G.; Schenk, U.; Wood, J.; Burri, P. H.; Hubbell, J. A.; Zisch, A. H. *Circ. Res.* **2004**, *94*, 1124–1132.
- (181) Arnljots, B.; Dahlback, B. *Arterioscler., Thromb., Vasc. Biol.* **1995**, *15*, 937–941.
- (182) Hardhammar, P. A.; van Beusekom, H. M.; Emanuelsson, H. U.; Hofma, S. H.; Albertsson, P. A.; Verdouw, P. D.; Boersma, E.; Serruys, P. W.; van der Giessen, W. J. *Circulation* **1996**, *93*, 423–430.
- (183) Serruys, P. W.; Emanuelsson, H.; van der Giessen, W.; Lunn, A. C.; Kiemeny, F.; Macaya, C.; Rutsch, W.; Heyndrickx, G.; Suryapranata, H.; Legrand, V.; Goy, J. J.; Materne, P.; Bonnier, H.; Morice, M. C.; Fajadet, J.; Belardi, J.; Colombo, A.; Garcia, E.; Ruygrok, P.; de Jaegere, P.; Morel, M. A. *Circulation* **1996**, *93*, 412–422.
- (184) Serruys, P. W.; van Hout, B.; Bonnier, H.; Legrand, V.; Garcia, E.; Macaya, C.; Sousa, E.; van der Giessen, W.; Colombo, A.; Seabra-Gomes, R.; Kiemeny, F.; Ruygrok, P.; Ormiston, J.; Emanuelsson, H.; Fajadet, J.; Haude, M.; Klugmann, S.; Morel, M. A. *Lancet* **1998**, *352*, 673–681.
- (185) Haude, M.; Konorza, T. F.; Kalnins, U.; Erglis, A.; Saunamaki, K.; Glogar, H. D.; Grube, E.; Gil, R.; Serra, A.; Richardt, H. G.; Sick, P.; Erbel, R. *Circulation* **2003**, *107*, 1265–1270.
- (186) Wohlr, J.; Al-Khayer, E.; Grotzinger, U.; Schindler, C.; Kochs, M.; Hombach, V.; Hoher, M. *Eur. Heart J.* **2001**, *22*, 1808–1816.
- (187) Lin, P. H.; Chronos, N. A.; Marjaniowski, M. M.; Chen, C.; Conklin, B.; Bush, R. L.; Lumsden, A. B.; Hanson, S. R. *J. Surg. Res.* **2003**, *112*, 84–90.
- (188) Hietala, E. M.; Maasilta, P.; Valimaa, T.; Harjula, A. L.; Tormala, P.; Salminen, U. S.; Lassila, R. J. *Biomed. Mater. Res., Part A* **2003**, *67*, 785–791.
- (189) Christensen, K.; Larsson, R.; Emanuelsson, H.; Elgue, G.; Larsson, A. *Thromb. Res.* **2005**, *115*, 245–253.
- (190) Castellot, J. J., Jr.; Pukac, L. A.; Caleb, B. L.; Wright, T. C., Jr.; Karnovsky, M. J. *J. Cell Biol.* **1989**, *109*, 3147–3155.
- (191) Letourneur, D.; Caleb, B. L.; Castellot, J. J., Jr. *J. Cell. Physiol.* **1995**, *165*, 676–686.
- (192) Rogers, C.; Karnovsky, M. J.; Edelman, E. R. *Circulation* **1993**, *88*, 1215–1221.
- (193) Thomas, A. C.; Campbell, J. H. *Atherosclerosis* **2004**, *176*, 73–81.
- (194) Thomas, A. C.; Campbell, J. H. *J. Controlled Release* **2004**, *100*, 357–377.
- (195) Matsumoto, Y.; Shimokawa, H.; Morishige, K.; Eto, Y.; Takeshita, A. *J. Cardiovasc. Pharmacol.* **2002**, *39*, 513–522.
- (196) Hanke, H.; Oberhoff, M.; Hanke, S.; Hassenstein, S.; Kamenz, J.; Schmid, K. M.; Betz, E.; Karsch, K. R. *Circulation* **1992**, *85*, 1548–1556.
- (197) Weitz, J. I. *N. Engl. J. Med.* **1997**, *337*, 688–698.
- (198) Norrby, K. *APMIS* **2006**, *114*, 79–102.
- (199) Koromila, G.; Michanetzis, G. P.; Missirlis, Y. F.; Antimisariis, S. G. *Biomaterials* **2006**, *27*, 2525–2533.
- (200) Verheye, S.; Markou, C. P.; Salame, M. Y.; Wan, B.; King, S. B., 3rd; Robinson, K. A.; Chronos, N. A.; Hanson, S. R. *Arterioscler., Thromb., Vasc. Biol.* **2000**, *20*, 1168–1172.
- (201) Thierry, B.; Winnik, F. M.; Merhi, Y.; Silver, J.; Tabrizian, M. *Biomacromolecules* **2003**, *4*, 1564–1571.
- (202) Thierry, B.; Merhi, Y.; Silver, J.; Tabrizian, M. *J. Biomed. Mater. Res., Part A* **2005**, *75*, 556–566.
- (203) Hought, W. H.; Sokol, M.; Kerensky, R. A.; Mehta, J. L. *Am. J. Cardiol.* **1995**, *76*, 314–315.

- (204) Gossman, D. E.; Schneider, F. *Catheter. Cardiovasc. Diagn.* **1996**, 38, 56–61.
- (205) Deux, J. F.; Prigent-Richard, S.; d'Angelo, G.; Feldman, L. J.; Puvion, E.; Logeart-Avramoglou, D.; Pelle, A.; Boudghene, F. P.; Michel, J. B.; Letourneur, D. *J. Vasc. Surg.* **2002**, 35, 973–981.
- (206) Anastase-Ravion, S.; Carreno, M. P.; Blondin, C.; Ravion, O.; Champion, J.; Chaubet, F.; Haeffner-Cavaillon, N.; Letourneur, D. *J. Biomed. Mater. Res.* **2002**, 60, 375–383.
- (207) Patel, M. K.; Mulloy, B.; Gallagher, K. L.; O'Brien, L.; Hughes, A. D. *Thromb. Haemostasis* **2002**, 87, 149–154.
- (208) Chabut, D.; Fischer, A. M.; Collic-Jouault, S.; Laurendeau, I.; Matou, S.; Le Bonniec, B.; Helley, D. *Mol. Pharmacol.* **2003**, 64, 696–702.
- (209) Luyt, C. E.; Meddahi-Pelle, A.; Ho-Tin-Noe, B.; Collic-Jouault, S.; Guezennec, J.; Louedec, L.; Prats, H.; Jacob, M. P.; Osborne-Pellegrin, M.; Letourneur, D.; Michel, J. B. *J. Pharmacol. Exp. Ther.* **2003**, 305, 24–30.
- (210) Deux, J. F.; Meddahi-Pelle, A.; Le Blanche, A. F.; Feldman, L. J.; Collic-Jouault, S.; Bree, F.; Boudghene, F.; Michel, J. B.; Letourneur, D. *Arterioscler., Thromb., Vasc. Biol.* **2002**, 22, 1604–1609.
- (211) Nugent, H. M.; Edelman, E. R. *Circ. Res.* **2003**, 92, 1068–1078.
- (212) Panetta, C. J.; Miyauchi, K.; Berry, D.; Simari, R. D.; Holmes, D. R.; Schwartz, R. S.; Caplice, N. M. *Hum. Gene Ther.* **2002**, 13, 433–441.
- (213) Shirota, T.; Yasui, H.; Matsuda, T. *Tissue Eng.* **2003**, 9, 473–485.
- (214) Shirota, T.; Yasui, H.; Shimokawa, H.; Matsuda, T. *Biomaterials* **2003**, 24, 2295–2302.
- (215) Aoki, J.; Serruys, P. W.; van Beusekom, H.; Ong, A. T.; McFadden, E. P.; Sianos, G.; van der Giessen, W. J.; Regar, E.; de Feyter, P. J.; Davis, H. R.; Rowland, S.; Kutryk, M. J. *J. Am. Coll. Cardiol.* **2005**, 45, 1574–1579.
- (216) Yeh, H. I.; Lu, S. K.; Tian, T. Y.; Hong, R. C.; Lee, W. H.; Tsai, C. H. *J. Biomed. Mater. Res., Part A* **2006**, 76, 835–841.
- (217) Lambiase, P. D.; Edwards, R. J.; Anthopoulos, P.; Rahman, S.; Meng, Y. G.; Bucknall, C. A.; Redwood, S. R.; Pearson, J. D.; Marber, M. S. *Circulation* **2004**, 109, 2986–2992.
- (218) Schmidt-Lucke, C.; Rossig, L.; Fichtlscherer, S.; Vasa, M.; Britten, M.; Kamper, U.; Dimmeler, S.; Zeiher, A. M. *Circulation* **2005**, 111, 2981–2987.
- (219) Labhasetwar, V.; Song, C.; Humphrey, W.; Shebuski, R.; Levy, R. J. *J. Pharm. Sci.* **1998**, 87, 1229–1234.
- (220) Panyam, J.; Labhasetwar, V. *Adv. Drug Delivery Rev.* **2003**, 55, 329–347.
- (221) Chorny, M.; Fishbein, I.; Danenberg, H. D.; Golomb, G. J. *Controlled Release* **2002**, 83, 389–400.
- (222) Banai, S.; Chorny, M.; Gertz, S. D.; Fishbein, I.; Gao, J.; Perez, L.; Lazarovich, G.; Gazit, A.; Levitzki, A.; Golomb, G. *Biomaterials* **2005**, 26, 451–461.
- (223) Ganaha, F.; Kao, E. Y.; Wong, H.; Elkins, C. J.; Lee, J.; Modanlou, S.; Rhee, C.; Kuo, M. D.; Yuksel, E.; Cifra, P. N.; Waugh, J. M.; Dake, M. D. *J. Vasc. Interv. Radiol.* **2004**, 15, 601–608.
- (224) Kolodgie, F. D.; John, M.; Khurana, C.; Farb, A.; Wilson, P. S.; Acampado, E.; Desai, N.; Soon-Shiong, P.; Virmani, R. *Circulation* **2002**, 106, 1195–1198.
- (225) Zilberman, M.; Schwade, N. D.; Eberhart, R. C. *J. Biomed. Mater. Res., Part B* **2004**, 69, 1–10.
- (226) Grainger, D. W.; Castner, D. G. *Adv. Mater.*, in press.
- (227) Lanza, G. M.; Yu, X.; Winter, P. M.; Abendschein, D. R.; Karukstis, K. K.; Scott, M. J.; Chinen, L. K.; Fuhrhop, R. W.; Scherrer, D. E.; Wickline, S. A. *Circulation* **2002**, 106, 2842–2847.
- (228) Pislaru, S. V.; Harbuzariu, A.; Gulati, R.; Witt, T.; Sandhu, N. P.; Simari, R. D.; Sandhu, G. S. *J. Am. Coll. Cardiol.* **2006**, 48, 1839–1845.
- (229) Edelman, E. R.; Rogers, C. *Circulation* **1999**, 100, 896–898.
- (230) Rogers, C.; Edelman, E. R. *Circulation* **2006**, 113, 2262–2265.

BM700540P